Claritev (CTEV) AI Stock Analysis

• Market Cap: $528.16M
• Dividend Yield: N/A
• Average Volume (3M): 232.53K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.89
• Revenue Growth: 0.89%
• EPS Growth: 78.04%
• Country: US
• Employees: 2,700
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -4.23
• Shares Outstanding: 16,525,644
• 10 Day Avg. Volume: 354,363
• 30 Day Avg. Volume: 232,525
• PEG Ratio: >-0.01
• Price to Book (P/B): 5.61
• Price to Sales (P/S): 0.51
• P/FCF Ratio: -44.88
• Enterprise Value/Market Cap: 10.37
• Enterprise Value/Revenue: 5.76
• Enterprise Value/Gross Profit: 7.71
• Enterprise Value/Ebitda: 13.23
• 1Y Price Target: $62.00
• Price Target Upside: 31.58% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: $32.00 ▼(-32.09% Downside)

Claritev's overall stock score is primarily impacted by its financial instability and poor valuation metrics. Despite positive earnings call highlights and strategic corporate events, the company's high leverage and negative profitability weigh heavily on its score.

Positive Factors

Revenue Growth

Consistent revenue and EBITDA growth indicate strong market demand and effective business strategies, supporting long-term expansion.

Client Renewals

Renewing major client contracts enhances revenue stability and strengthens market position, ensuring sustained business relationships.

Strategic Investments

Investments in technology and AI drive innovation and competitive advantage, positioning Claritev for future growth and market leadership.

Negative Factors

Financial Leverage

High leverage and negative equity indicate financial instability, posing risks to long-term financial health and operational flexibility.

Profitability Challenges

Ongoing profitability issues reflect cost management challenges, potentially impacting long-term sustainability and investment capacity.

Cash Flow Challenges

Negative free cash flow highlights cash management issues, limiting the company's ability to invest in growth and manage debt effectively.

Claritev Business Overview & Revenue Model

Company Description

Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers analytics-based services that reduce medical costs, through data-driven algorithms and insights that detect claims over-charges and negotiate or recommend reimbursement; and network-based services that provide contracted discounts with healthcare providers, as well as outsourced network development and management services. It provides payment and revenue integrity services, such as identifying and removing improper and unnecessary charges paid during the claim, as well as services to identify and help restore and preserve underpaid premium dollars. In addition, the company offers data and decision science services including a suite of solutions that apply modern methods of data science to produce descriptive, predictive, and prescriptive analytics that drive optimized benefit plan design, support decision-making, improve clinical outcomes, and reduce the total cost of care; and business-to-business healthcare payments and other services. It serves national and regional insurance companies, Blue Cross and Blue Shield plans, provider-sponsored and independent health plans, TPAs, self-insured health plans, property and casualty insurers, bill review companies, and other companies involved in the claim adjudication process. The company was formerly known as MultiPlan Corporation and changed its name to Claritev Corporation in February 2025. Claritev Corporation was founded in 1980 and is headquartered in New York, New York.

How the Company Makes Money

Claritev generates revenue through a subscription-based model for its cloud services, charging clients monthly or annually for access to its platforms. Additionally, the company offers consulting services that help organizations implement data analytics solutions, which contributes to a significant portion of its revenue. Key partnerships with major cloud service providers and healthcare institutions also play a crucial role in driving sales and expanding its customer base, further enhancing its revenue streams.

Claritev Financial Statement Overview

Summary

Claritev faces significant financial challenges with a negative net profit margin and high leverage. Despite revenue growth, profitability and cash flow issues pose risks to long-term sustainability.

Income Statement

Claritev's income statement reveals significant challenges. The TTM data shows a negative net profit margin of -126.96%, indicating substantial losses. Revenue growth is positive at 87.3% TTM, but this is overshadowed by negative EBIT and EBITDA margins, suggesting operational inefficiencies. Historical data shows a declining trend in profitability, with consistent negative net income over the years.

Balance Sheet

The balance sheet highlights financial instability, with a concerning debt-to-equity ratio of 312.43 in the TTM period, reflecting high leverage. Stockholders' equity is negative, indicating potential solvency issues. The return on equity is also negative, suggesting poor returns for shareholders. These factors point to significant financial risk.

Cash Flow

Cash flow analysis shows mixed results. The operating cash flow to net income ratio is positive at 0.15 TTM, indicating some cash generation capability. However, free cash flow is negative, and its growth rate is declining, which could impact future liquidity. The free cash flow to net income ratio is also negative, reflecting cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	951.00M	930.62M	961.52M	1.08B	1.12B	937.76M
Gross Profit	710.55M	691.22M	726.06M	875.62M	942.31M	619.09M
EBITDA	414.06M	-1.01B	651.93M	158.32M	814.99M	192.41M
Net Income	-341.68M	-1.65B	-91.70M	-572.91M	102.08M	-520.56M
Balance Sheet
Total Assets	4.99B	5.15B	6.96B	7.37B	8.22B	8.28B
Cash, Cash Equivalents and Short-Term Investments	50.65M	16.85M	71.55M	334.05M	185.33M	126.75M
Total Debt	4.65B	4.54B	4.57B	4.78B	4.93B	4.61B
Total Liabilities	5.09B	5.07B	5.26B	5.58B	5.88B	5.73B
Stockholders Equity	-101.83M	84.02M	1.71B	1.79B	2.34B	2.56B
Cash Flow
Free Cash Flow	-113.12M	-10.51M	62.87M	282.63M	320.10M	306.56M
Operating Cash Flow	17.01M	107.62M	171.72M	372.36M	404.69M	377.37M
Investing Cash Flow	-116.79M	-118.12M	-249.79M	-104.45M	-228.38M	-210.84M
Financing Cash Flow	53.26M	-41.31M	-180.99M	-115.74M	-114.68M	-61.60M

Claritev Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 47.12
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTEV, the sentiment is Negative. The current price of 47.12 is above the 20-day moving average (MA) of 37.36, above the 50-day MA of 44.14, and above the 200-day MA of 44.33, indicating a bearish trend. The MACD of -3.54 indicates Positive momentum. The RSI at 39.90 is Neutral, neither overbought nor oversold. The STOCH value of 18.94 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTEV.

Claritev Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NUTX	80 Outperform	$1.28B	8.95	63.86%	―	236.03%	―
HSTM	69 Neutral	$668.42M	32.29	5.87%	0.52%	3.68%	5.62%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HCAT	50 Neutral	$174.00M	-1.52	-31.33%	―	4.64%	-17.17%
DH	49 Neutral	$359.80M	-1.47	-47.69%	―	-5.30%	46.01%
EVH	48 Neutral	$463.14M	-2.55	-13.63%	―	-16.65%	-71.92%
CTEV	47 Neutral	$528.16M	-1.55	-646.34%	―	0.89%	78.04%

Claritev Corporate Events

Claritev Ends Former CEO’s Strategic Advisory Role

Claritev Corporation disclosed a governance update involving its former Chief Executive Officer and Executive Chair, Dale White, who currently serves on the company’s board of directors. On December 23, 2025, the company announced that White will end his role as a strategic advisor effective December 31, 2025, a position he assumed after stepping down as Executive Chair on December 31, 2024; he will remain a director on the board, the company waived its right to require 30 days’ notice for ending the advisory role, and no additional compensation will be paid for that advisory service, signaling a formal conclusion to his transitional duties while preserving his board-level involvement.

The most recent analyst rating on (CTEV) stock is a Hold with a $32.00 price target. To see the full list of analyst forecasts on Claritev stock, see the CTEV Stock Forecast page.

Claritev Finalizes Underwriting Agreement for Stock Sale

On November 12, 2025, Claritev Corporation entered into an Underwriting Agreement with affiliates of Hellman & Friedman and several underwriters for the sale of 1,500,000 shares of Class A common stock at $51.50 per share. The Offering, which closed on November 14, 2025, did not involve the company selling shares or receiving proceeds, and included a 30-day option for underwriters to purchase an additional 225,000 shares.

The most recent analyst rating on (CTEV) stock is a Hold with a $43.00 price target. To see the full list of analyst forecasts on Claritev stock, see the CTEV Stock Forecast page.

Claritev Secures Renewals with Major Clients

On October 15, 2025, Claritev Corporation successfully renewed contracts with its ten largest clients, representing approximately 70% of its 2024 revenues. By extending these long-term agreements, Claritev aims to reinforce its commitment to stability and growth, enhancing its industry positioning and ensuring continued partnerships with core clients.

The most recent analyst rating on (CTEV) stock is a Hold with a $54.00 price target. To see the full list of analyst forecasts on Claritev stock, see the CTEV Stock Forecast page.